Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda's Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization of Dymista; Cipla will take responsibility for formulation. According to Meda, the company will "now have full coverage in … [Read more...] about Meda and Cipla expand Dymista partnership; Meda denies talk of sale to Sun
News
Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company's GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher doses of oral pirfenidone. Genoa said that it would present data at an upcoming pulmonary … [Read more...] about Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study
Elan gets injunction against Royalty Pharma
Irish biotech company Elan, which recently paid $1 billion to Theravance for royalty payments from sales of Breo (Relvar) Ellipta and other inhaled drugs, has been awarded an injunction against Royalty Pharma by an Irish court. The order restrains Royalty Pharma from distributing a proxy statement to Elan shareholders. Royalty Pharma has been seeking to acquire … [Read more...] about Elan gets injunction against Royalty Pharma
Johnson & Johnson developing ketamine nasal spray for depression
According to reports, Johnson & Johnson described development of a ketamine nasal spray for the treatment of depression during a meeting with analysts on May 23, 2013. The product is not listed among the company's pipeline drugs in a document dated April 16, 2013 on the J&J website. Reportedly, J&J's nasal spray is a formulation of esketamine, an isomer of … [Read more...] about Johnson & Johnson developing ketamine nasal spray for depression
New nasal research consortium “The Oz Nose Project” announced
A new consortium described as a "series of conceptual research projects in the area of nasal physiology, function and drug delivery" that "aims to enhance understanding in the area of upper respiratory tract disorders and develop methodological approaches that can be utilized via the wider scientific community" has been announced. Researchers involved in the … [Read more...] about New nasal research consortium “The Oz Nose Project” announced
Study shows significant overdiagnosis of COPD
A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth Health Center in Youngstown assessed 80 patients at a health center in Akron, Ohio using spirometry. All of the patients had either been diagnosed with COPD or … [Read more...] about Study shows significant overdiagnosis of COPD
Prosonix begins Phase 2 study of inhaled glycopyrronium bromide
Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered particles is delivered by pMDI. Prosonix CEO David Hipkiss commented, “This trial with PSX1002 is a … [Read more...] about Prosonix begins Phase 2 study of inhaled glycopyrronium bromide
Grifols licenses Aradigm’s inhaled ciprofloxacin formulations
Grifols is paying $25 million upfront, plus up to $25 million in milestone payments to acquire a worldwide license for Aradigm’s Pulmaquin and Lipoquin inhaled ciprofloxacin formulations. Grifols will also pay tiered royalties on worldwide sales of products using the formulations and will be responsible for up to $65 million in expenses for Phase 3 development and … [Read more...] about Grifols licenses Aradigm’s inhaled ciprofloxacin formulations
Malvern and Proveris team on spray characterization system
Malvern Instruments has announced that it will team up with Proveris Scientific Corporation on a nasal spray characterization system called Solo for Spraytec, which combines Proveris's automated actuator and software for precise control of device actuation with Malvern's Spraytec laser diffraction particle size analyzer. The FDA recommends laser diffraction for … [Read more...] about Malvern and Proveris team on spray characterization system
Vectura announces reduced losses, new CFO
Inhaled drug developer Vectura has announced better than expected preliminary results for the year ending March 31, 2013, with the company's loss before tax 21% lower than in 2011/12. The company also announced that Paul Oliver will replace Anne Hyland as CFO. Vectura CEO Chris Blackwell said, “The past year has been very significant for Vectura, driven by the … [Read more...] about Vectura announces reduced losses, new CFO